Incretin Atlas › Trials › HARBOR-1 (HRS-7535-303, NCT06904105)
HARBOR-1 (HRS-7535-303, NCT06904105)
HRS-7535 · obesity
Design
- Molecule(s)
- HRS-7535
- Population
- obesity
- Official title
- A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Phase
- 3
- Registry status
- completed · 2025-04 → 2026-04
- Participants
- 556
- Duration
- 44 weeks
- Registry
- NCT06904105
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120 mg | obesity china | 44 | 556 | −9.5 % vs −2.5 % Δ −7.0 pp | −8.0 % vs −2.4 % Δ −5.6 pp | — | 4.1 vs 2.7 | — | 70.3 vs 16.2 | 66.7 vs 4.5 | — | — | press release |
| 180 mg | obesity china | 44 | 556 | −10.9 % vs −2.5 % Δ −8.4 pp | −9.8 % vs −2.4 % Δ −7.4 pp | — | 3.1 vs 2.7 | — | 70.0 vs 16.2 | 68.6 vs 4.5 | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (10)
- 120 mg · weight_tp · press release
Based on the treatment policy estimand^2, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 8.0% and 9.8% from baseline at Week 44, respectively, compared to 2.4% with placebo.
- 120 mg · nausea · press release
nausea (70.3% and 70.0% vs. 16.2% with placebo)
- 120 mg · vomiting · press release
vomiting (66.7% and 68.6% vs. 4.5% with placebo)
- 120 mg · ae_dc · press release
Treatment discontinuation rates due to TEAEs were 4.1% (120 mg) and 3.1% (180 mg) for HRS-7535 vs. 2.7% with placebo.
- 120 mg · weight_eff · press release
Based on the efficacy estimand^1, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 9.5% and 10.9% from baseline at Week 44, respectively, compared to 2.5% with placebo.
- 180 mg · weight_tp · press release
Based on the treatment policy estimand^2, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 8.0% and 9.8% from baseline at Week 44, respectively, compared to 2.4% with placebo.
- 180 mg · nausea · press release
nausea (70.3% and 70.0% vs. 16.2% with placebo)
- 180 mg · vomiting · press release
vomiting (66.7% and 68.6% vs. 4.5% with placebo)
- 180 mg · ae_dc · press release
Treatment discontinuation rates due to TEAEs were 4.1% (120 mg) and 3.1% (180 mg) for HRS-7535 vs. 2.7% with placebo.
- 180 mg · weight_eff · press release
Based on the efficacy estimand^1, participants taking HRS-7535 120 mg and 180 mg achieved a mean weight loss of 9.5% and 10.9% from baseline at Week 44, respectively, compared to 2.5% with placebo.
Primary sources
- Kailera / Hengrui. Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of HRS-7535/KAI-7535 (HARBOR-1, OUTSTAND-2) (GlobeNewswire via BioSpace) [press release]. 2026-07-07. Available from: https://www.biospace.com/press-releases/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-kai-7535
- ClinicalTrials.gov NCT06904105
How to cite this page
Medical Adviser's Group. Incretin Atlas: HARBOR-1 (HRS-7535-303, NCT06904105). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/harbor-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.